February 1, 2013 (Vol. 33, No. 3)

Zafgen added Patricia Allen as CFO. Formerly, Allen served as vp of finance, treasurer, and principal financial officer of Alnylam Pharmaceuticals. Prior to that, she was the corporate controller and director of finance at Alkermes. Allen began her career as an auditor at Deloitte & Touche.

Patricia Allen

AMAG Pharmaceuticals hired Greg Madison as evp and CCO…CytoDyn appointed Sam Zakhem as Middle East business consultant…Health Discovery promoted John Norris as its new CEO…Relypsa named Paul J. Hastings and David W. J. McGirr to its board of directors.

Coronado Biosciences hired Harlan F. Weisman, M.D., as chairman and CEO. Most recently, Dr. Weisman held a number of leadership positions at Johnson and Johnson. Before that he was the head of R&D at Centocor. He was also on the board of directors at J&J Development.

Harlan F. Weisman, M.D.

NewLink Genetics added Brian Wiley as cp of business development…Christopher S. Destro joined Atossa Genetics as vp of sales and marketing…Bruce E. Schneider, Ph.D., is now CEO at Omni Bio Pharmaceutical…CytRx promoted Daniel Levitt, M.D., Ph.D., to evp.

Alison Lawton joined OvaScience as COO. Prior to joining OvaScience, she was svp and general manager at Genzyme Biosurgery. Before that, Lawton was svp of global market access at Genzyme. She is currently a board member of Cubist Pharmaceuticals and Verastem.

Alison Lawton

ImmunoCellular Therapeutics appointed Gary S. Titus to its board of directors…TVAX Biomedical added Philip Haworth, Ph.D., as CEO…Ambrx named Lawson Macartney, Ph.D., as president, CEO, and to its board of directors…Orgenesis hired Sav DiPasquale as president and CEO…Alexza Pharmaceuticals appointed J. Kevin Buchi to its board of directors…Rolland Carlson, Ph.D., is now president and CEO of Asuragen.

Cubist Pharmaceuticals added Thomas J. DesRosier as svp, chief legal officer, and secretary. Currently, he is svp, general counsel North America of Sanofi. He also served as svp, chief legal officer at Genzyme. Prior to that he was at Wyeth Pharmaceuticals.

Thomas J. DesRosier

CorMedix promoted Randy Milby to CEO and Richard M. Cohen to CFO…Coherus BioSciences named V. Bryan Lawlis Jr., Ph.D., as chairman of its scientific advisory board…Omicia appointed Mike Aicher as CEO and to its board of directors…Hookipa Biotech appointed Stanley Plotkin, M.D., Michael Mach, Ph.D., Arnaud Marchant, M.D., Ph.D., and Franz Heinz, Ph.D., to its scientific advisory board; Paul-Henri Lambert, Ph.D., as chair of the board; and Thomas Monath, M.D., as CMO.

Tim Mayleben is now president and CEO of Esperion Therapeutics. Previously, Mayleben was president and CEO at Aastrom Biosciences. Prior to that, he was president, COO, and a director of NightHawk Radiology. He also served as COO and CFO at Esperion Therapeutics.

Tim Mayleben

Savient Pharmaceuticals named David Meeker, M.D., to its board of directors…Joan E. Shaw is now with AtheroNova as senior director of clinical operations…Steve Glaza joined SNBL as director of safety assessment…Rib-X Pharmaceuticals appointed Mary Szela as chair of its board of directors…Interleukin Genetics hired Scott Snyder as CMO…ArborGen named Richard I. Eisenstadt as CFO…Biothera added John P. Atkinson, M.D., to its research advisory board…Medistem appointed John Chiplin, Ph.D., to its board of directors.

Predictive Biosciences named Pierre Cassigneul CEO. Previously, he served as vice chairman of the board, president, and CEO of XDx. Additionally, he has held management positions at Becton Dickinson, Bayer Diagnostics, Ortho Diagnostic Systems, and Abbott Laboratories.

Pierre Cassigneul

David Tran joined PAC as vp of product management and marketing…Endocyte named Lesley Russell to its board of directors…Particle Sciences hired Deepak Tiwari, Ph.D., as director, formulation, and process development…Cyberonics added Bruce H. KenKnight, Ph.D., as vp, emerging therapies…Aqeel Fatmi, Ph.D., is now evp of global research and development and CSO at Patheon.

Hookipa Biotech appointed Farshad Guirakhoo, Ph.D., as CSO. Prior to this, Dr. Guirakhoo was senior director of external research and development at Sanofi Pasteur, and he spent 15 years at Acambis, where he headed research and co-invented the ChimeriVax-technology platform.

Farshad Guirakhoo, Ph.D.

Send your People Announcements to [email protected]

Previous articleWandering Tumor Cells May Seed Metastasis in Breast Cancer
Next articleMerck Dampens 2013 Expectations After Q4 Profits Slide